title: Poor prognosis of prethymic phenotype acute lymphoblastic leukemia (pre-T-ALL).
abstract: Pre-T-ALL is an important subgroup of ALL with clinical features different from adult T-ALL. Expression of intracytoplasmic CD3 represents the earliest marker for the prethymic phenotype. We studied four consecutive adult patients with this phenotype. Three of the four patients did not respond to the induction chemotherapy with vincristine, daunorubicin, prednisone and asparaginase. They reached a delayed remission only after chemotherapy with cyclophosphamide and cytosine arabinoside. All four patients relapsed 3, 9, 10 and 13 months after diagnosis. One patient died 2 months after relapse, another one 2 months after allogeneic BMT performed in second relapse. We conclude that patients with early T-cell precursor leukemia do not respond adequately to conventional chemotherapy and should be considered as a high-risk subgroup within the T-lineage ALL.
authors.affiliation: Department of Internal Medicine I (Haematology/Oncology), Albert-Ludwigs University of Freiburg, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Digel
authors.forename: J
authors.initials: J
authors.lastname: Schultze
authors.forename: R
authors.initials: R
authors.lastname: Kunzmann
authors.forename: R
authors.initials: R
authors.lastname: Mertelsmann
authors.forename: A
authors.initials: A
authors.lastname: Lindemann
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D001402:B-Lymphocytes / Q000276:immunology; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D016130:Immunophenotyping; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011289:Preleukemia / Q000188:drug therapy* / Q000276:immunology; D011379:Prognosis; D012074:Remission Induction; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D015703:Antigens, CD; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D001215:Asparaginase; D011241:Prednisone; D003630:Daunorubicin